# A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06631989/  
OnCo record `nct06631989` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of WSD0922-FU in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.

## Summary

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06631989 by Wayshine Biopharm, Inc., with 100 participants planned, started 2024-09-04 and due to reach its primary completion in 2027-06-30. Interventions recorded: WSD0922-FU.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06631989
- Phase: 1/2
- Setting: A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer
- Sponsor: Wayshine Biopharm, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06631989: https://clinicaltrials.gov/study/NCT06631989

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06631989.json